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Abstract
In scleroderma (systemic sclerosis, SSc), persistent activation of myofibroblast leads to se-
vere skin and organ fibrosis resistant to therapy. Increased mechanical stiffness in the in-
volved fibrotic tissues is a hallmark clinical feature and a cause of disabling symptoms.
Myocardin Related Transcription Factor-A (MRTF-A) is a transcriptional co-activator that is
sequestered in the cytoplasm and translocates to the nucleus under mechanical stress or
growth factor stimulation. Our objective was to determine if MRTF-A is activated in the dis-
ease microenvironment to produce more extracellular matrix in progressive SSc. Immuno-
histochemistry studies demonstrate that nuclear translocation of MRTF-A in scleroderma
tissues occurs in keratinocytes, endothelial cells, infiltrating inflammatory cells, and dermal
fibroblasts, consistent with enhanced signaling in multiple cell lineages exposed to the stiff
extracellular matrix. Inhibition of MRTF-A nuclear translocation or knockdown of MRTF-A
synthesis abolishes the SSc myofibroblast enhanced basal contractility and synthesis of
type I collagen and inhibits the matricellular profibrotic protein, connective tissue growth fac-
tor (CCN2/CTGF). In MRTF-A null mice, basal skin and lung stiffness was abnormally re-
duced and associated with altered fibrillar collagen. MRTF-A has a role in SSc fibrosis
acting as a central regulator linking mechanical cues to adverse remodeling of the extracel-
lular matrix.
Introduction
Scleroderma (systemic sclerosis, SSc), a severe connective tissue disease with a high mortality
rate affecting 1 in 8,000 people, is characterized by progressive fibrosis of skin and internal or-
gans [1]. The pathobiology of this disease includes vascular injury, autoimmunity, and
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that no competing interests exist.inflammation culminating in fibrosis, which disrupts the architecture of the dermis and multi-
ple internal organs through an accumulation of extracellular matrix (ECM) rich in type I colla-
gen [1–4]. The clinical subset, diffuse cutaneous SSc, is most extensive with a more severe
overall fibrotic phenotype than other clinical subtypes [5]. Although biomechanical measure-
ments of skin stiffness vary depending on site, all sites in diffuse SSc patients are stiffer than
healthy controls [6]. In forearm skin, Young’s modulus, a measure of stiffness, is 50–80 kPa in
diffuse SSc compared to 4–12 kPa in healthy individuals [7]. Collagen fibrils are considered the
primary ECM protein responsible for biomechanics of tissue [8]. Skin thickness and stiffness
correlates with increased myofibroblasts [9] and large (90–120 nm) diameter collagen fibrils
[10]. Skin thickening and tightness are the hallmark clinical changes of SSc, and severity of the
skin fibrosis correlates with mortality and overall outcome.
Myofibroblasts that mediate fibrosis contain α-smooth muscle actin (SMA) and deposit
ECM composed of collagen and matricellular proteins such as connective tissue growth factor
(CCN2/CTGF) [1, 3, 11]. SMA is regulated at the transcriptional level by serum response factor
(SRF) and co-activators of the myocardin family [12]. Myocardin, a potent nuclear transcrip-
tional co-activator expressed in cardiac and smooth muscle lineages, is required for smooth
muscle specific gene expression [13]. The myocardin-related transcription factors, MRTF-A
(also called MKL1/MAL/BSAC) and MRTF-B (also called MKL2), are ubiquitously expressed
[14]. Signals of stress, mechanical force and migration activate Rho GTPases resulting in actin
cytoskeleton polymerization into stress fibers, permitting nuclear translocation of MRTFs
which link actin dynamics with gene transcription [15–17]. Once in the nucleus, the myocardin
family drives transcription of cytoskeleton genes including SMA as well as CCN2 [16]. Myocar-
din family members interact with SRF as homo- or heterodimers to stimulate transcription via
conserved CArG box DNA elements [18]. Our data demonstrates that MRTF-A, not other
family members, drives collagen (COL1A2) transcription and this regulation is largely SRF in-
dependent [19]. MRTF-A nuclear translocation can be blocked by the pharmacological inhibi-
tor, CCG-1423, [20, 21] originally described as a Rho inhibitor [22] thus blocking the Rho/
SRF/MRTF pathway.
Transforming growth factor β (TGFβ)-induced myofibroblast differentiation is considered
a key feature of SSc fibrosis [23]. Contractile myofibroblasts, as well as epithelial cells, have
been shown to release TGFβ from latency associated peptide via an integrin dependent mecha-
nism which leads to enhanced signaling via TGFβ receptor complexes [24, 25]. Exposure to
TGFβ activates MRTF-A [26, 27] and MRTF-A has been described as a critical mediator of
TGFβ-induced epithelial to mesenchymal transition (EMT) [28, 29] as well as endothelial to
mesenchymal (EndMT) transition [30] resulting in myofibroblast like cells. MRTF-A has been
implicated in mechanical sensing of ECM to determine cell fate decisions [15, 31–36]. In par-
ticular, matrix stiffness, tensional homeostasis, and mechanical force induce myofibroblast dif-
ferentiation through MRTF-A [12, 37–40]. Previously, MRTF-A loss-of-function mice (KO)
have been shown to be resistant to cardiac fibrosis [41], hypoxia induced pulmonary hyperten-
sion [42], bleomycin induced lung fibrosis [38], and skin fibrosis [43]. Fibroblasts from
MRTF-A KO mice [44] produce less collagen which can be rescued by over-expressing
MRTF-A [19]. In addition, the cells do not transcribe more collagen driven GFP in response to
TGFβ [45]. These data suggest that following injury, exposure to activated TGFβ, or stress,
MRTF-A is activated to induce myofibroblast differentiation and collagen production from
multiple cell types. It has been proposed that there is a feed forward mechanism for progression
of fibrosis [38] such that during fibrosis, cells continue to respond to matrix stiffening produc-
ing abnormal amounts of ECM.
Our hypothesis is that MRTF-A is progressively activated in SSc and that inhibition of
MRTF-A nuclear translocation or expression may alter the progression of fibrosis in SSc and
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human skin and demonstrates that MRTF-A expression in the nucleus is increased in multiple
cell types within the SSc skin. Knockdown of MRTF-A and inhibition of MRTF-A nuclear
translocation by CCG-1423 abrogates collagen and the fibrotic matricellular protein CCN2
synthesis and cell contraction by SSc fibroblasts. In addition, we show that the KO MRTF-A
mice display decreased stiffness and mechanical properties in skin and lungs, through altered
collagen fibrils.
Materials and Methods
Study subjects and ethical statements
Boston University Medical Center and the UCL, Royal Free Hospital Institutional Review
Board (IRB) approved all human studies performed at each location. All scleroderma patients
fulfilled the American College of Rheumatology criteria for disease and were classified accord-
ing to internationally accepted criteria [46]. All study subjects and healthy volunteers gave
written informed consent. Punch biopsy samples (3 mm Boston, 4 mm London) of the skin
over the dorsal midforearm were collected and prepared for histology at Boston University by
DermPath Core, part of the National Scleroderma Center (Figs 1 and 2, S1 and S2 Figs). For
the London Studies, conducted under the Royal Free Hospital IRB, patients were classified as
early SSc if within the first 2 years of disease onset, defined by the appearance of the first non-
Raynaud’s manifestation. Patients with disease duration above 2 years were classified as estab-
lished as previously described [47]. Punch biopsy samples were prepared for histology by
pathology at UCL Medical School (Fig 3) or placed in media for cell culture (Figs 4 and 5). Pa-
tients were not receiving immunosuppressive medication or corticosteroids at the time of biop-
sy if cells were cultured.
The Boston University School of Medicine Institutional Animal Care and Use Committee
(IACUC) approved all animal husbandry and experiments for isolation of cells and tissue
(Figs 4B, 6 and 7). The UCL, Royal Free Hospital Comparative Biology Unit (CBU) Ethics and
Welfare Committee approved all the London animal handling for cell culture of mouse dermal
cells (S3 Fig).
Histology
Biopsies of human skin were fixed in 4% paraformaldehyde embedded in paraffin, sectioned
(5 μm) and stained using standard techniques. Sections were incubated with antibodies against
MRTF-A (Santa Cruz C-19), MRTF-B (Sigma Prestige, USA), procollagen (Abcam, ab64409),
and SMA (Sigma, USA) developed with alkaline phosphatase red reagent or horseradish perox-
idase with DAB (3, 3’-diaminobenzidine) and counter stained with hematoxylin. For MRTF-A
antibody, sections were treated for antigen retrieval at pH6, secondary antibody with alkaline
phosphatase and counter stained with hematoxylin. MRTF-A localization to the cell nucleus
was quantified by counting of immunostained (brown) nuclei versus hematoxylin stained nu-
clei (blue) per high power field. Nuclei were counted in 5 slides for each individual (N = 5
healthy controls, N = 9 SSc) and expressed as percentage of MRTF-A positive nuclei, mean and
SEM for controls and SSc patients. Procollagen staining in cells was quantified by counting the
number of brown stained cells in the papillary dermis of healthy controls (N = 4), early SSc
(N = 3) and late SSc (N = 3). For transmission electron microscopy, samples were fixed using
standard methods [48]. At least >200 fibrils from five different micrographs (40,000 magnifi-
cation) within the dermis of each sample (N = 4 KO, N = 4 WT) were measured using ImageJ
(NIH) to calculate an average fibril diameter.
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The MRTF-A loss of function mice (kindly supplied by Eric Olson) [44] were mated to mice
transgenic with COL1A1 3.6 kb promoter driving GFPtopaz in C57/Bl6 background (kindly
supplied by David Rowe)[49]. Lung cells from mice were extracted as described [19] and cul-
tured at 60% density on fibronectin coated polyacrylamide gels in 6 well dishes [50]( Fig 4B).
Five pictures were taken of each well and the numbers of cells and pixel density was quantified
using ImageJ software. A second mouse colony was established at Royal Free Hospital London
approved by the CBU Ethics and Welfare Committee according to European laws and regula-
tions for the use and protection of vertebrate mammals for experimentation and other scientif-
ic purposes. Mouse and human dermal cell culture were isolated in London as described [51].
Fibroblasts were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand
Island, NY) supplemented with 10% fetal bovine serum (Atlanta Biologicals or Gibco), 1% pen-
icillin/streptomycin and incubated in 5% CO2 at 37°C. For some experiments cells were treated
with TGFβ (R&D Systems) or grown on collagen type I coated polyacrylamide plates at 5 and
50 kPa (Softwell Collagen, Matrigen Products)(Figs 4A, 4C, 4D and 5).
Fig 1. MRTF-A expression is more prominent in SSc skin then healthy control. MRTF-A staining
(1:1000) of healthy control (left) and SSc (right) sections. Several pictures across the wound were merged to
produce panoramas of whole sections. Original magnification 10X. Expression of MRTF-A is increased in
SSc sections, with more seen in dermal cells, keratinocytes, and vasculature especially within inflammatory
foci around small vessels in SSc. Arrow indicate sweat and sebaceous glands (SG), vascularture (V) or
inflamatory foci (IF) stained with MRTFs. 1. MRTF-A vascular cell staining in healthy controls or 2.
pervascular inflammtory foci in SSc. (30X).
doi:10.1371/journal.pone.0126015.g001
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Specific siRNA recognizing MRTF-A was purchased as predesigned siRNAs to MRTF-A
(Dharmafect SMARTpool On TARGETplus MKL1 siRNA) alone or with a recommended
non-target control siRNA (Ambion, Warrington, UK). Normal and SSc fibroblasts were trans-
fected using Silencer siRNA Transfection II Kit (Ambion, Applied Biosystems, Warrington
UK) with 60 nM siRNA. Cells were then used in floating collagen gel assay and for protein de-
terminations by Western analysis.
Floating collagen gel contraction assay
Experiments were performed as described previously [52]. Briefly, collagen/cell suspension
(80,000 cells with 1.2 mg/ml collagen (Vitrogen)) was added to each bovine serum albumin
coated wells (24-well plates). After polymerization, gels were detached from wells. In some ex-
periments, CCG-1423 was added to medium. Contraction of the gel was quantified by loss of
gel weight and decrease in gel diameter over a 24-h time period.
Western analysis
Fibroblasts from monolayer culture were collected and lysed with 8 M urea and 1% SDS sample
buffer or nuclei and cytoplasm was separated using NE-PER (Thermo Scientific). Proteins
were quantified (Bradford, Bio-Rad, Hercules, California, USA), and equal amounts (25 μg)
were subjected to SDS/PAGE using 4% to 12% polyacrylamide gels (Invitrogen, Paisley, UK).
Fig 2. Nuclear MRTF-A expression is more prominent in SSc skin then healthy control. A. Representative pictures of healthy control and SSc sections
of biopsy. Histological samples of human skin were stained with MRTF-A antibody (1:2000). Higher magnification of epithelium and small vessels (20X)i n
papillary dermis. Brown arrows = MRTF-A nuclei, Blue arrow = hematoxylin stained nuclei without MRTF-A. Graphical representations of % nuclei in
epidermis, vasculature, and interstitial cells in papillary dermis. Histological samples of 5 healthy control and 9 scleroderma human skin were evaluated for
nuclear staining. B. Total cells with MRTF-A nuclear localization in the epidermis, vasculature, and interstitial papillary dermal layers were counted and
compared with the total amount of nuclei in the epidermal/papillary dermal layer. White bars = healthy controls, Black bars = SSc (* =p <0.01 using
nonparametric Mann-Whitney U, two-tailed).
doi:10.1371/journal.pone.0126015.g002
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UK), anti-SMA (Sigma, USA), anti-procollagen (Millipore, UK) and an enhanced chemilumi-
nescence (Amersham, Little Chalfont, UK). Densitometry was performed using Quantity One
software (Bio-Rad, Hercules, California, USA).
Measurement of mechanical properties of skin and lungs
Dorsal skin from WT (N = 6) and aged-matched MRTF-A KO mice (N = 6) were shaved and
cut into strips (3x1x1 mm) and orientated parallel to the spine. Lung tissue strips were obtained
from the same animals. Uniaxial quasi-static stress-strain curves and oscillatory stress-strain
loops were obtained as previously [53]. The strips were preconditioned by applying three trian-
gular waves stretching the samples up to 40% strain at a rate of 0.75%/s. After a 5-min equili-
bration period, a quasi-static stress-strain curve was taken followed by dynamic measurements
between 0.05 and 0.8 Hz with 40% strain for seven cycles. Force and length data were recorded
and converted to stress and strain, respectively, using the dimensions of the strips.
Statistics
The statistical significance was assessed by nonparametric Mann-Whitney test, ANOVA with
Scheff post-hoc or Tukey post-hoc or paired t-test. P 0.05 was considered as
statistically significant.
Fig 3. Increased expression of MRTF-A in the SSc epidermis and at the epidermal dermal junction in
established SSc correlates with increased intracellular procollagen, and SMA. The expression of
MRTF-A, procollagen type I, and SMA was detected by immunohistochemical staining in the epidermis and
papillary dermis of early and established SSc patients and controls healthy control patients. Arrows point to
staining in vascular cells (V), epidermis (e), and fibroblast (F).
doi:10.1371/journal.pone.0126015.g003
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MRTFs are up-regulated in multiple cell lineages within SSc skin
Since MRTF-A translocates to nucleus in response to mechanical stiffness, which is increased
in SSc skin, the expression and location of MRTF proteins were examined in patients with dif-
fuse SSc. MRTF-A was more widely expressed in SSc skin then in healthy controls as judged by
immunochemistry (Figs 1, 2, and 3). Antigen peptide blocking and IgG controls demonstrated
that MRTF-A staining was specific (S1 Fig). MRTF-A staining was most obvious in cytoplasm
of epidermal derived cells such as keratinocytes, sebaceous glands and sweat glands in normal
tissue biopsy which was increased in most SSc patients (Fig 1).
SSc disease starts with an initial vascular damage and subsequent inflammatory cell infiltra-
tions surrounding small blood vessels in the papillary dermis [54]. Normal skin had MRTF-A
staining in small vessels (Fig 1A, insets) suggestive of endothelial or pericyte expression within
the normal microvasculature in the papillary dermis (Figs 1A and 2). MRTF-A in endothelial
cells activates the adhesion molecule intercellular adhesion molecule 1, (ICAM-1), and
endothelin through the inflammatory molecule nuclear factor kappa B (NFκB) subunit p65
and epigenetic modulating enzymes [55, 56]. Both these MRTF-A targets are increased [57]
and function in SSc [58, 59]. MRTF-A also mediates TGFβ-induced endothelial to mesenchy-
mal transition [30] which is important in SSc [60]. In SSc dermis with inflammatory foci, there
is extensive MRTF-A staining (Fig 1A insets). Inflammatory foci contains activated macro-
phages [61]. In cultured macrophages, MRTF-A mediates synthesis of pro-inflamatory mole-
cules such as tumor necrosis factor (TNFα)[ 62, 63] that are increased in SSc early disease [64].
Fig 4. Stiff surfaces and TGFβ induce MRTF-A nuclear accumulation. SSc and control dermal fibroblast
lines (both N = 3) were cultured on 6 well plates with collagen type I coated soft substrates (5 kPa Softwell), or
hard substrate (50 kPa). B. Induction of collagen transcription on hard surfaces requires MRTF-A.
Mouse fibroblasts from wild type (WT) and loss-of-function (KO) mice with collagen promoter driving GFP
were cultured on fibronectin coated soft and hard surfaces. Pictures taken 24 hours after plating.
Fluorescence was quantified using ImageJ. The numbers of cells in each image was counted (S4 Fig)t o
determine the luminance per cell. C.&D. Normal control fibroblasts and SSc fibroblasts were cultured without
serum for 16 hours then treated with TGFβ (4 ng/ml) for 0, 8 and 24 hours or treated with either saline or
TGFβ (4 ng/ml) with or without CCG1423 (10μM) or NSC2376 (50 μM). Proteins (20 μg) from cytoplasm and
nuclei were extracted using NE-PER Nuclear Protein Extraction Kit and separated on 4–12% gradient gel
and visualized using MRTF-A antibody.
doi:10.1371/journal.pone.0126015.g004
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vessel growth and maturation through CCN1 and CCN2 [65].
MRTF-A is predominantly nuclear in SSc skin
Since MRTF-A translocates to the nucleus to act as a transcription co-activator, the percentage
of nuclear MRTF-A was calculated for multiple cell types (Fig 2). In healthy control skin
(N = 5), keratinocytes (45%±6), fibroblasts (61%±11) and vascular (56%±14) cells in microves-
sels had nuclear MRTF-A staining in the papillary dermis (Fig 2). There was significantly more
nuclear MRTF-A staining in SSc keratinocytes (N = 9) (64%±10), dermal fibroblasts (88%±8),
and vascular cells (87%±10) (Fig 2). Compared with healthy controls, the SSc dermis contained
extensive MRTF-A staining within inflammatory foci in the perivascular area surrounding ves-
sels (Fig 1A).
Keratinocyte activation in SSc is correlated to increased nuclear
localization of MRTF-A
Previous data from our group demonstrated that SSc epidermis is activated with delayed kerati-
nocyte differentiation and changes resembling those seen during wound healing [47, 66, 67].
Here we show MRTF-A nuclear staining of healthy control epidermis was concentrated in the
basal area in normal keratinocytes (Fig 3, top panels). The keratinocytes in SSc exhibited
Fig 5. Enhanced type I collagen and CCN2 expression as well as collagen gel contraction in
scleroderma fibroblasts is dependent on MRTF-A pathway. A. The MRTF-A inhibitor, CCG-1423,
blocks collagen and CCN2 synthesis. Healthy control fibroblasts (Control) and scleroderma fibroblasts
(SSc) from 3 independent isolates were cultured with or without the MRTF-A inhibitor CCG-1423 (10 μM).
Basal CCN2 and type I collagen was increased in scleroderma cells and inhibited by CCG-1423. B.
Knockdown of MRTF-A by siRNA blocks collagen and CCN2 synthesis in SSc fibroblasts. Control and
SSc fibroblasts were treated with MRTF-A siRNA, (siMRTFA), a non-target siRNA (siNT), or vehicle (Cont).
C. Loss or inhibition of MRTF-A blocks contraction of collagen floating gels. Knockdown (siMRTFA)
and inhibition (CCG-1423) of MRTF-A partially blocks collagen floating gel contraction by SSc fibroblasts.
* =p <0.05.
doi:10.1371/journal.pone.0126015.g005
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lung tissue was placed longitudinally into a computer-controlled dual-mode lever arm force transducer
system and stretched intermittently. A. Young’s module plotted at each strain. The Young’s module is the
slope of the stress-strain curve. B. Dynamic stretch storage modulus describes the ability of the material to
store elastic energy during the loading phase of a cyclic stretch C. Dynamic stretch loss modulus—The
amount of energy lost (usually as heat) during a cycle. Vertical brackets denote the overall group differences
using 2-way repeated measure ANOVA (*: p<0.05, **: p<0.01 and ***: p<0.001) whereas horizontal
brackets show Tukey’s post hoc differences between WT and KO at the same strain (Panel A) or frequency
(Panels B and C). For the Young’s and loss moduli of lung tissue, there are also significant interactions
between strain and group (panel A) as well as frequency and group (panel C, p<0.05). For the skin, there is a
significant interaction between frequency and group only for the loss modulus (p<0.05).
doi:10.1371/journal.pone.0126015.g006
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suggesting activation of keratinocytes. A key role of MRTF-A in keratinocyte biology was
shown previously by Watt and colleaques, who demonstrated that basal keratinocytes prolifer-
ate until encountering a physically constrained environment whereupon they release MRTF-A
from actin and signal to induce involucrin and the terminal differentiation program [68]. Our
recent data suggests that classical terminal differentiation markers are extended downwards to
the spinous layer keratinocytes, with all but basal cells positive for involucrin [47]. Characteris-
tically, SSc cells are taking on an altered pathway of differentiation, expressing activation mark-
ers, wound related cytokeratins, and premature expression of maturation markers such as
involucrin, a known target of MRTF-A [47]. In addition, MRTF-A is an important downstream
signal during TGFβ induced-EMT [28]. Since SMA is a direct target of MRTF-A in EMT, the
same patient’s slides were examined using a SMA antibody (Fig 3, bottom panels). Several late
stage patients with highest levels of nuclear MRTF-A have SMA staining in the keratinocytes
suggesting partial EMT. Furthermore, in SSc, the activated epidermal cells are able to release
factors capable of inducing local dermal fibroblasts to become, CCN2 producing cells [47, 66,
Fig 7. Fibril diameters in the KO reticular dermis are smaller and more uniform than WT fibrils. A. Representative micrographs of skin in deep dermal
areas near subcutaneous fat. (Scale bar = 0.5 μm) B. Histogram of the frequency of collagen fibrils with a given diameter range from WT (white bars) and KO
(black bars). At least 200 fibrils from 3 WT and 3 KO animals at 5 months of age were used for analysis. P<0.05.
doi:10.1371/journal.pone.0126015.g007
MRTF-A in Scleroderma Fibrosis
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proliferation and to enhances fibroblast CCN2 expression [47].
SSc cells within the epidermal-dermal juncture have increased nuclear
MRTF-A and collagen
Our previous data demonstrates that Collagen type I is a direct transcriptional target of
MRTF-A [19]. Therefore, sections were examined using a procollagen I antibody directed at
the N-terminal propeptide. The staining was predominantly cytoplasmic consistent with local
cells producing collagen. In late stage SSc when stiffness is highest, there were significantly
more cells (2 fold) staining with collagen (Fig 3, middle panels). The papillary dermis contains
activated fibroblasts producing collagen with no SMA staining other than vascular cells (Fig 3,
bottom panels, and S2 Fig). ECM collagen staining at the epidermal-dermal border was noted
in healthy and early SSc (Fig 3, middle panels) presumably newly synthesized small collagen
fibrils maintaining the N-terminal propeptide [69]. Small diameter type III/type I fibrils (20–
40 nm) containing N-terminal propeptides are normally found at the epidermal/dermal junc-
ture [69]. In late stage SSc, there was less N-terminal peptide staining in the ECM (Fig 3). This
agrees with earlier studies that reported increased numbers of larger diameter (80–120 nm) col-
lagen fibrils with no N-terminal peptides in SSc papillary and reticular dermis [10].
Reticular dermis in SSc skin contain cells with nuclear MRTF-A that
express SMA
In later stages of SSc, collagen accumulates leading to increased dermal thickening with a loss
of microvasculature and fibrosis of the reticular dermis and subcutaneous adipose tissue. In
order to examine the correlation of nuclear MRTF-A with SMA expression that identify myofi-
broblasts, a series of patient’s biopsies were stained for MRTF-A and consecutive slides were
stained for SMA. Dermal SMA+ myofibroblasts in established SSc were primarily located in re-
ticular dermis with strong SMA+ and MRTF-A nuclear staining (S2 Fig). MRTF-A regulates
myofibroblast differentiation through mechanotransduction [33] which is a process whereby a
living cell converts mechanical cues to biochemical signals maintained by a physical continuity
between the ECM/integrin/cytoskeleton/nuclear matrix structures [70]. Fibroblasts in the pap-
illary dermis exhibited nuclear MRTF-A staining, but limited SMA staining other than micro-
vessels. Erector pili muscles were strongly SMA+ with a subset of nuclear MRTF-A staining
muscle cells (50% in normal muscle, 90% in SSc). Epithelial structures (sebaceous and sweat
glands) were stained in the cytoplasm with MRTF-A, with little staining of SMA. In the epider-
mal-dermal juncture region, MRTF-A staining was present in the endothelial cell nuclei in
small papillary vessels next to the cells staining for SMA (pericytes and/or smooth muscle
cells). In established disease, myofibroblasts are present primarily in the reticular dermis not in
the papillary dermis.
MRTF-A translocates to the nucleus on stiff fibrotic-like matrices or by
TGFβ
Activation of MRTF-A may be part of a feed forward mechanism whereby cells sense stiff ma-
trix and produce more ECM during progression of fibrosis in SSc [38]. Changes in mechanical
environment were modeled in vitro by growing SSc and healthy control fibroblasts on soft or
stiff collagen coated polyacrylamide gels (Softwell 5 kPa vs 50 kPa). The increased substrate
stiffness enhanced nuclear translocation of MRTF-A in dermal fibroblasts (Fig 4A). The SSc
cells had more nuclear MRTF-A on soft and stiff matrices than healthy control cells similar to
MRTF-A in Scleroderma Fibrosis
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mimicking normal skin stiffness.
Most importanly, collagen expression and synthesis increases on stiffer matrices [71]. To ex-
amine whether MRTF-A controls collagen expression with stiffness, MRTF-A KO mice [44]
were bred to transgenic mice with an integrated copy of 3.6kb Col1A1 promoter driving
GFPtopaz [49] to measure fluorescence as previously described [19]. Isolated lung cells from
WT and MRTF-A KO transgenic mice, produce less collagen which can be rescued by over-ex-
pressing MRTF-A [19]. In addition, the cells do not transcribe more collagen driven GFP in re-
sponse to TGFβ [45]. Lung cells from WT and KO mice were grown on polyacrylamide gel
substrates functionalized with fibronectin to encourage myofibroblast differentiation [50]. WT
cell proliferation, collagen production and transcription were increased on surfaces with simi-
lar stiffness to fibrotic tissue. Without MRTF-A, collagen transcription and proliferation were
not increased on fibrotic-like surfaces (Fig 4B and 4S). The intensity of fluorescence per cell de-
creased in KO cells on fibrotic-like matrices. These KO cells did not modulate their collagen
transcription on stiff matrix (Fig 4B). Others have also demonstrated that MRTF-A directs
myofibroblast differentiation and SMA expression on stiff matrices [27]. Our data suggests
that the increase in collagen on stiffer matrix is MRTF-A dependent.
Since TGFβ enhances MRTF-A translocation in cell specific manner [28, 72], SSc and con-
trol fibroblasts were plated on soft matrix (5 kPa) and treated with TGFβ to determine if fi-
brotic and normal cells differ. Nuclear MRTF-A was present at very low levels in control
fibroblasts, but was strongly present in scleroderma cells. TGFβ stimulated nuclear accumula-
tion of MRTF-A levels after 8 hours in both SSc and healthy controls which reverted back to
baseline levels by 24 hours (Fig 4C). Our results suggest that baseline amounts of nuclear
MRTF-A are elevated in SSc cells and TGFβ-induced translocation of MRTF-A occurs in
healthy control fibroblasts. Since the pharmacological inhibitor, CCG-1423, blocks MRTF-A
nuclear translocation [20, 21], SSc and healthy control cells were treated with CCG-1423 to de-
termine if it would inhibit TGF-β-induced translocation of MRTF-A. As shown in Fig 4D,
CCG-1423 blocked TGF-β-induced MRTF-A translocation (Fig 4D). Rac1 is essential for re-
pair mechanism [73] and knockout of Rac1 decreases bleomycin induced fibrosis [74]. Since
Rac1 signaling has been implicated in MRTF-A signaling [75], cells were also treated with a
Rac inhibitor, NSC23766 [76]. However, Rac1 inhibition did not alter MRTF-A nuclear
translocation.
CCG-1423 and MRTF-A knockdown decreases collagen, SMA, and
CCN2 expression in SSc cells
Cultured early passage dermal fibroblasts from patients with SSc have a basal pro-fibrotic phe-
notype and maintain their ability to synthesize more collagen and CCN2 in tissue culture [77,
78]. In order to determine whether the phenotype is dependent on MRTF-A, control and SSc
dermal fibroblasts were treated with CCG-1423 to determine if inhibition of MRTF-A nuclear
translocation would decrease collagen, SMA and CCN2, an important profibrotic cytokine.
Compared to controls, basal levels of type I collagen, SMA, and CCN2 were elevated in SSc fi-
broblasts. CCG-1423 decreased collagen, SMA, and CCN2 levels in both control and SSc fibro-
blasts (Fig 5A). Knocking down MRTF-A with siRNA also reduced collagen and CCN2
expression, especially in SSc fibroblasts, similar to the pharmacological inhibitor (Fig 5B). The
enhanced synthesis of ECM molecules by SSc cells was dependent on nuclear MRTF-A expres-
sion and nuclear localization.
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An important function of myofibroblasts is contraction [78], which was measured by growing
cells in floating 3D collagen gels. As shown previously [52], SSc fibroblasts contracted the colla-
gen gels significantly more than healthy control fibroblasts (Fig 5C) through stimulation of the
TGFβ activation pathway [79, 80]. The MRTF-A siRNA and CCG-1423 blocked collagen gel
contraction by SSc fibroblasts but did not alter contraction of healthy controls. Isolated fibro-
blasts from WT mice contracted the gels significantly more than KO fibroblasts (S3 Fig)a s
shown by others [81]. Since TGFβ increases contraction, gels were treated with and without
TGFβ. TGFβ treatment increased contraction of normal cells, but not KO cells (S3 Fig). When
MRTF-A was either inhibited by CCG-1423 or knocked down by MRTF-A siRNA in WT fi-
broblasts, TGFβ-induced contraction was diminished, whereas TGFβ-induced contraction was
not significantly altered in MRTF-A KO fibroblasts. This strongly suggests that nuclear
MRTF-A is required for fibrotic myofibroblast function and the inhibitor not only alters colla-
gen and CCN2 synthesis but also collagen gel contraction.
Loss of functional MRTF-A decreases mechanical stress and stiffness of
skin and lungs
Since collagen synthesis by KO cells is lower than WT cells [19] and MRTF-A translocation is
induced by mechanical stiffness, the biomechanical properties of dermal and lung tissue in KO
mice were tested. Skin and lung tissue strips obtained from MRTF-A KO and WT mice were
quasi-statically and dynamically stretched. The KO mice developed less stress and showed
lower stiffness than normal mice in both dermal and lung tissue during quasi-static stretch (Fig
6A). The Young’s modulus from KO dermis was 45% lower than WT at 36% strain (p<0.01).
Dynamic oscillatory data confirmed that tissues from KO mice were significantly less stiff than
tissues from WT mice with both storage (Fig 6B) and loss (Fig 6C) moduli increasing with fre-
quency. These data suggest that MRTF-A not only responds to stiffness, but actually creates a
stiffer ECM in multiple organs. Mice deficient in MRTF-A have a basal level of mechanical
stress that is reduced in the dermis consistent with resetting of the mechanical stress-adhesion-
contraction mechanism (Fig 6). Areas of increased stiffness correlates with areas rich in colla-
gen [71].
Dermal collagen fibrils in KO mouse are smaller and more uniform
Since the biomechanical data suggest that there is less collagen or looser arrangement of fibrils
in the KO mice, skin was prepared for electron microscopy to examine collagen fibrils. The di-
ameters of collagen fibrils from WT and KO were quantified from EM micrographs (Fig 7). Al-
though the KO papillary dermis fibrils were not significantly different than the WT, collagen
fibrils in the reticular dermis, deep in the dermis near the adipose tissue, were significantly
smaller (KO mean 57 nm, WT 97 nm) and more uniform in size than wild type mice. The re-
sults of this study are remarkably similar to the matricellular protein secreted protein acidic
and rich in cysteine (SPARC/osteonectin) null mouse where the deficiency of SPARC reduced
the collagen fibril diameter with more uniform distribution in the reticular dermis and de-
creased the skin tensile strength [82]. In SSc with activated MRTF-A, collagen fibrils are 2–3
times more abundant with larger variations in fibril diameters [10]. The difference between
reticular and papillary dermis may be an important distinction since reticular and papillary
dermis cells may have distinct lineages [83]. In SSc dermis in established disease, the myofibro-
blasts are present primarily in the reticular dermis. The papillary dermis has cells with nuclear
MRTF-A but without SMA other than vascular cells.
MRTF-A in Scleroderma Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0126015 May 8, 2015 13 / 20Conclusion
Skin and organ based fibrosis in SSc remains a challenging condition to treat because once es-
tablished, fibrosis is mantained by a feedforward loop of increased adhesion, contractility, and
increased mechanical stress leading to further myofibroblast differentiation and matrix modifi-
cation. MRTF-A is recognized as a major mechanosensitive signaling molecule that, following
mechanical force, is released from cytoplasmic G-actin and translocates to the nucleus to acti-
vate gene transcription of multiple genes in a cell specific manner [15, 17]. Outside of the con-
text of SSc, a number of published studies support the notion that MRTF-A signaling has an
essential role in fibrosis in different disease settings including LPA induced peritoneal fibrosis
and pulmonary fibrosis; as well as bowel; hepatic and renal fibrosis [84–89]. Our data, repre-
sents the first examination of MRTF-A expression in human skin and demonstrates that
MRTF-A expression in the nucleus is increased in several cell types in vasculature, inflammato-
ry foci and fibroblasts to activate multiple targets within the SSc skin. In Scc, through environ-
ment stress genetically predisposed individuals develop endothelial cell damage and activation,
as well as perivascular infiltration of inflammatory immune cells into the affected dermis. Epi-
dermal cells also become activated taking on a tissue repair phenotype. These cell populations
induce resident fibroblasts via cross talk, leading to myofibroblast differentiation, contractility,
and initiation of ECM modifications, which increase mechanical stress. MRTF-A links me-
chanical stress to a harmful feed-forward mechanism via the induction of pro-fibrotic/tissue
repair genes. CCG-1423, an inhibitor of nuclear translocation of MRTF-A [20, 90], reduces
contractility and suppresses fibrotic targets in SSc fibroblasts. It is possible that drug therapies
which target MRTF-A signaling could uncouple the persistent fibrosis from mechanical stress
in SSc tissues leading to resolution or improvement, or would improve the responses to immu-
nosuppressive or targeted anti-inflammatory treatments.
Supporting Information
S1 Fig. SSc section stained with MRTF-A antibody compared to isotype IgG and blocking
antibody controls indicate that antibody is specific. Histological samples of human skin of
SSc patient was stained with MRTF-A antibody (Santa Cruz C-19) (1:2000), IgG control, or
with antibody and blocking peptide. Sections were counterstained with hematoxylin. Brown
arrow points to MRTF-A nuclei, Blue arrow points to nuclei without MRTF-A.
(TIF)
S2 Fig. Serial sections were stained with MRTF-A and SMA. A Several pictures across the
skin were merged to produce panoramas of whole sections. Original magnifications 10X. Ar-
rows point to vascular (V), erector pilus muscle (M), fibroblast (F) and myofibroblasts (MF).
Line on SSc sections represent the separation between papillary and reticular dermis. Boxes
with numbers represent the higher powered pictures in B—D. B. Higher magnification (20X)
of papillary dermis with small vessels. SMA staining in myofibroblasts below the dotted line.
MRTF-A nuclear staining without SMA above the line other than is vasculature. C. Papillary/
Reticular dermis with erector pilus muscle D. Reticular dermis of same patient with myofibro-
blasts and adipose tissue staining in SSc, but not in normal skin sections.
(TIF)
S3 Fig. MRTF-A is required for collagen gel contraction in mouse cells. A. Collagen gel con-
traction was significantly reduced in MRTF-A deficient cultures. KO cells did not contract the
collagen gel even with the addition of TGFβ. TGFβ increased collagen contraction in WT.
CCG-1423 blocked the contraction in the WT but not in the KO.  =p <0.01 WT vs TGFβ
treated WT,  =p <0.005 KO vs WT control. B. Knockdown of MRTF-A by siRNA blocks
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siMRTFA = MRTF-A siRNA.
(TIF)
S4 Fig. Bright field pictures of fluorescent cells in Fig 4B.
(TIF)
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